Trial Profile
A Double-Blind, Placebo-Controlled, Once-Weekly, Multiple-Dose Study to Investigate the Safety, Tolerability, Plasma Concentration Profile and Effects on Biochemical Markers of Bone Resorption of MK0822 in Healthy Postmenopausal Female Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary)
- Indications Bone resorption; Postmenopausal osteoporosis
- Focus Adverse reactions
- Sponsors Merck & Co; Merck Sharp & Dohme
- 17 Apr 2020 Results (n=1280) of pooled analysis from phase 1 (P005, P025, and P014), phase 2b (P004 and P022), and phase 3 (P018) , assessing population pharmacokinetic (PK) model in postmenopausal women for odanacatib, published in the Journal of Clinical Pharmacology
- 01 Aug 2009 Results published in Clinical Pharmacology and Therapeutics.
- 23 Oct 2008 New trial record.